Please login to the form below
Novavax
This page shows the latest Novavax news and features for those working in and with pharma, biotech and healthcare.
US trial data shows Novavax’s COVID-19 vaccine is 90% effective
In a statement, Novavax said sequence data was available for 54 of the 77 COVID-19 cases observed in the trial. ... By the end of the fourth quarter of 2021, Novavax said it is also on track to manufacture 150 million doses per month.
Latest news
-
Novavax announces further delays for regulatory filings of COVID-19 vaccine
Novavax is also expecting data from a US-based phase 3 trial of its COVID-19 vaccine, involving 30, 000 volunteers, in “a few weeks”, according to Erck. ... Based on this information, Novavax calculated that its vaccine is 95.6% effective against the
-
Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
Earlier this year, reports emerged that Novavax has encountered issues with sourcing some raw materials used in the manufacturing process for NVX-CoV2373. ... The UK government has already signed an advanced purchase agreement with Novavax for 60 million
-
Moderna agrees to supply Gavi with 500 million doses for COVAX
A number of other major vaccine developers have previously signed supply agreements with COVAX, including Sanofi and GlaxoSmithKline, Pfizer/BioNTech and AstraZeneca, while Novavax recently announced a memorandum of understanding with
-
GSK’s revenue drops by 18% in Q1 as performance pressures mount
agreement to help make Novavax’s vaccine candidate.
-
Oxford University’s malaria vaccine is 77% effective
Two groups were allocated to received the R21/Matrix-M vaccine – either with a low dose or high dose of Novavax’s Matrix-M adjuvant – while the third control group received
Novavax announces further delays for regulatory filings of COVID-19 vaccine
Moderna agrees to supply Gavi with 500 million doses for COVAX
GSK’s revenue drops by 18% in Q1 as performance pressures mount
Oxford University’s malaria vaccine is 77% effective
More from news
Approximately 17 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Developing a COVID-19 vaccine
The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
-
Deal Watch table for June 2013
30. Isconova / Novavax. Acquisition. Proprietary vaccine adjuvant technology. 30. Unless noted, transactions are for global rights.
Developing a COVID-19 vaccine
Deal Watch table for June 2013
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.
Dutch biotech Mucosis promotes Thomas Johnston to CEO
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
